bioRxiv · 10.1101/2022.09.06.506720
MAGE enables population level RNAseq driven genotyping and (differential) allelic divergence detection in healthy kidney and carcinoma
Abstract
Decreasing sequencing costs have instigated large-scale RNAseq experiments, yet genetic polymorphisms in such data remain poorly exploited. Currently, allele-specific expression (ASE) studies focus almost exclusively on genetic variants explaining expression differences (cis-eQTLs), largely ignoring other ASE effects. The latter are typically associated with higher variance in expression of both copies of a gene, here called Allelic Divergence (AD). We therefore developed an RNAseq-driven population-level beta-binomial mixture model for (differential) AD detection. The model simultaneously enables RNAseq-driven genotyping, which outperforms alternative RNA genotyping methods when applied on healthy kidney data from The Cancer Genome Atlas. Moreover, we identify well-known non-cis-eQTL ASE, e.g. random monoallelic expression of HLA and immunoglobulin genes in healthy kidney, as well as allele-specific aberrations in clear cell kidney carcinoma, including long-range epigenetic silencing of protocadherins, copy-number alterations, and loss of imprinting. These methods are available as the Modeller of Allelic Gene Expression (MAGE) tool suite: https://biobix.github.io/MAGE/.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Stroobandt, C., Goovaerts, T., Coussement, L., De Graeve, F., Voorthuijzen, F., Van Steenbergen, L., Galle, J., Van Criekinge, W., De Meyer, T.. 2022-09-06. MAGE enables population level RNAseq driven genotyping and (differential) allelic divergence detection in healthy kidney and carcinoma. https://doi.org/10.1101/2022.09.06.506720
Cite the original work for its findings. Save a collection to share your selection of sources.